Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

repeatedly over nearly eight years to obtain a broader scope, but the USPTO rejected all of those attempts because multiple other researchers (including Dr. Liau and NW Bio) had already used dendritic cell treatments in a wide variety of sequences and timings with chemotherapies years before the Cedars Sinai/IMUC patent application was filed.  

Simply stated, NW Bio's DCVax product and treatment regimen do not fall within the narrow sequence and timing covered by the '090 patent.  The purpose and focus of NW Bio's clinical trials is to prove that DCVax is an effective treatment on its own.  Moreover, when NW Bio's DCVax reaches commercialization, the treating physician, not NW Bio, will be the party who administers DCVax, and who determines what further treatment to use in the event of recurrence.  NW Bio does not advise on post-recurrence therapies other than the use of its vaccine.  It is the physician who will determine whether to administer chemotherapy and, if so, which type of chemotherapy and in what manner. 

Additionally, all of these treatment activities can be undertaken by the physician free of the '090 patent in a variety of ways.  For example, step (b) of the patent was narrowed following USPTO rejections so as to include only the specific drugs listed. This list does not include the chemotherapy that doctors usually prescribe today after glioma recurrence (Avastin). 

  • The '090 patent is not applicable to treatment for most types of cancer.

Cedars Sinai/IMUC application sought a patent for "treating a disease condition in a mammal" but this was rejected by the USPTO.  Indeed, the USPTO would not even allow coverage of all cancers, or even all cancers of the central nervous system.  The patent claim was narrowed to just "treating a glioma in a mammal."  Glioma is only one of multiple sub-types of one cancer:  pr
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... Wis. , March 30, 2015  FUJIFILM Holdings ... and Cellular Dynamics International, Inc. (CEO: Robert J. ... developer and manufacturer of fully functioning human cells in ... two companies have entered into a definitive agreement whereby ... to be followed by a second step merger. Fujifilm ...
(Date:3/29/2015)... As a symbol of its commitment to ... manufacturing clients, Whitehouse Laboratories is excited to announce that ... Team for the 2015 race season. Success on the ... strong sense of precision and attention to detail. These ... the quality control testing laboratory. Sponsorship of the race ...
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Neogen CEO adopts 10b5-1 Trading Plan 2
... and LUND, Sweden, February 23 , ... Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement Surgery ... THR) and co-development partner,BioInvent International (OMXS: BINV) announce today ... II trial with their long-acting anticoagulant,TB-402 for the prophylaxis ...
... SANTA MONICA, Calif., Feb. 20 Cord Blood ... cord blood stem cell preservation company ( http://www.cordblood-america.com ... of stem cells to families nationwide and internationally, ... in an interview with analyst Francis Gaskins, provided ...
... Natural and Organic,Cosmetic* products are now identifiable at ... 100 products have already been certified as of ... NaTrue-Label provides orientation for consumers and manufacturers,alike by ... Organic,Cosmetics. It is international, not for profit, open ...
Cached Biology Technology:ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting 2NaTrue-Label: The First 100 Products are Certified 2
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
(Date:3/12/2015)... 12, 2015 IriTech, a leading iris based ... the Texas Instruments Design Network, announced today that the ... its IriShield USB MK2120U device during a launching event ... distribution. The iris scanner is manufactured ... in India through its Indian ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... (NAS) and Institute of Medicine (IOM) today released SCIENCE, ... public a comprehensive and up-to-date picture of the current ... science classroom. Recent advances in science and medicine, ... the past 150 years, have reinforced evolution,s role as ...
... the latest American Chemical Society (ACS) News Service Weekly PressPac ... Engineering News.,Please credit the individual journal or the American Chemical ... IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed ... ARTICLE #1 FOR IMMEDIATE RELEASE ...
... researchers have uncovered a critical difference between flu viruses that ... monitor the evolution of avian flu strains and aid in ... The researchers found that a virus,s ability to infect humans ... of receptor on the surface of human respiratory cells. ...
Cached Biology News:Scientific evidence supporting evolution continues to grow 2Scientific evidence supporting evolution continues to grow 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 2American Chemical Society's weekly PressPac -- Jan. 2, 2008 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 4American Chemical Society's weekly PressPac -- Jan. 2, 2008 5American Chemical Society's weekly PressPac -- Jan. 2, 2008 6American Chemical Society's weekly PressPac -- Jan. 2, 2008 7American Chemical Society's weekly PressPac -- Jan. 2, 2008 8American Chemical Society's weekly PressPac -- Jan. 2, 2008 9MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3